ReviewLife (Basel, Switzerland)2023
TIGIT in Lung Cancer: Potential Theranostic Implications.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB NSCLC.JTO clinical and research reports · 2026Article
- Association of FDG PET/CT and immune profiling with pathologic complete response after neoadjuvant immunotherapy in stage II-III non-small cell lung cancer.Translational lung cancer research · 2026Article
- CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection.International journal of clinical oncology · 2025Article
- TIGIT Regulates T Cell Inflammation in Airway Inflammatory Diseases.Inflammation · 2025Review
- Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy.EXCLI journal · 2025Review
- TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.Cancer immunology, immunotherapy : CII · 2024Article
- Potential Role of Circulating PD-L1Biomedicines · 2024Article
- Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.Journal of pathology and translational medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppression of immune responses. Recent studies have highlighted the importance of TIGIT in regulating immune cell function in the tumor microenvironment and its role as a potential therapeutic target, especially in the field of lung cancer. However, the role of TIGIT in cancer development and progression remains controversial, particularly regarding the relevance of its expression both in the tumor microenvironment and on tumor cells, with prognostic and predictive implications that remain to date essentially undisclosed. Here, we provide a review of the recent advances in TIGIT-blockade in lung cancer, and also insights on TIGIT relevance as an immunohistochemical biomarker and its possible theranostic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.